2. Search Result
Search Result
Isoforms Recommended: NNMT
Results for "

NNMT

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

2

Recombinant Proteins

2

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131042
    NNMTi
    5+ Cited Publications

    		 Amine N-methyltransferase Metabolic Disease
    NNMTi is a potent nicotinamide N-methyltransferase (NNMT) inhibitor (IC50=1.2 μM) and selectively binds to the NNMT substrate-binding site residues . NNMTi  promotes myoblast differentiation in vitro and enhances fusion and regenerative capacity of muscle stem cells (muSCs) in aged mice .
    NNMTi
  • HY-175603
    NCGC00685960

    		Amine N-methyltransferase Cancer
    NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 <10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research, such as ovarian cancer, breast cancer, colon cancer .
    NCGC00685960
  • HY-112584
    JBSNF-000088
    5+ Cited Publications

    6-Methoxynicotinamide

    		 Amine N-methyltransferase Metabolic Disease
    JBSNF-000088 (6-Methoxynicotinamide), a analog of nicotinamide (NA), is a potent and orally active Nicotinamide N-methyltransferase (NNMT) inhibitor with IC50s of 1.8 µM, 2.8 µM, and 5.0 µM for human NNMT, monkey NNMT and mouse NNMT, respectively. JBSNF-000088 inhibits NNMT activity, reduces MNA levels and drives insulin sensitization, glucose modulation and body weight reduction in animal models of metabolic disease .
    JBSNF-000088
  • HY-151500
    JBSNF-000028 free base

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 free base is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 free base can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 free base exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 free base can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028 free base
  • HY-151813
    NNMT-IN-4

    		Fluorescent Dye Cancer
    NNMT-IN-4 (compound 38) is a selective, uncompetitive and membrane permeability nicotinamide N-methyltransferase (NNMT) inhibitor with IC50 values of 42 and 38 nM in vitro biochemical and cell-based assays, respectively. NNMT-IN-4 shows favorable PK/PD and safety profiles as well as excellent oral bioavailability and pharmaceutical properties. NNMT-IN-4 can be used as a vivo chemical probe of NNMT .
    NNMT-IN-4
  • HY-138993A
    NNMT-IN-6 hydrochloride

    		Amine N-methyltransferase Cancer
    NNMT-IN-6 hydrochloride is a selective nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 of 1.41 μM and a Kd of 5.55 μM. NNMT-IN-6 hydrochloride exhibits selectivity over PRMT1 and NSD2. NNMT-IN-6 hydrochloride inhibits cancer cell proliferation and reduces cellular N-methylnicotinamide (MNA) production. NNMT-IN-6 hydrochloride can be used for the research of oral cancer .
    NNMT-IN-6 hydrochloride
  • HY-W093017
    4-Chloropyridine

    		Amine N-methyltransferase Others
    4-Chloropyridine is a NNMT (Nicotinamide N-methyltransferase) substrate and suicide inhibition-based protein labeling scaffold precursor.4-Chloropyridine undergoes NNMT-catalyzed pyridine nitrogen methylation to increase C4 electrophilicity, enabling aromatic nucleophilic substitution by NNMT cysteine C159 for covalent NNMT modification and inactivation.4-Chloropyridine can be used for the research of various cancers .
    4-Chloropyridine
  • HY-128464
    LL320

    		Amine N-methyltransferase Metabolic Disease
    LL320 is a selective NNMT inhibitor with a Ki,app of 6.8 nM. LL320 exhibits interactions with RNMT, DPH5, and SAHH .
    LL320
  • HY-151500B
    JBSNF-000028 hydrochloride

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 hydrochloride is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 hydrochloride can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 hydrochloride exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 hydrochloride can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028 hydrochloride
  • HY-151193
    NNMT-IN-3

    		Amine N-methyltransferase Metabolic Disease Cancer
    NNMT-IN-3 (Compound 14) is a potent and selective nicotinamide N-methyltransferase (NNMT) inhibitor, with IC50 values of 1.1 nM and 0.4 μM in cell-free and cell-based assays, respectively. NNMT-IN-3 can be used in the research of diseases such as obesity, type 2 diabetes and cancer .
    NNMT-IN-3
  • HY-138993
    NNMT-IN-6

    		Amine N-methyltransferase Cancer
    NNMT-IN-6 is a selective nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 of 1.41 μM and a Kd of 5.55 μM. NNMT-IN-6 hydrochloride exhibits selectivity over PRMT1 and NSD2. NNMT-IN-6 inhibits cancer cell proliferation and reduces cellular N-methylnicotinamide (MNA) production. NNMT-IN-6 can be used for the research of oral cancer .
    NNMT-IN-6
  • HY-161316
    NNMT-IN-5

    		Amine N-methyltransferase Neurological Disease Metabolic Disease Cancer
    NNMT-IN-5 (Compound 3-12) is a potent nicotinamide N-methyltransferase (NNMT) inhibitor (IC50 = 47.9 ± 0.6 nM). NNMT-IN-5 also has an excellent selectivity profile over a panel of human methyltransferases. NNMT-IN-5 can be used for the research of cancer, diabetes, metabolic disorders, and neurodegenerative diseases .
    NNMT-IN-5
  • HY-W1006754
    NNMT-IN-7

    		Amine N-methyltransferase Metabolic Disease
    NNMT-IN-7 (Compound 4e) is a NNMT inhibitor (IC50 = 505.7 µM). NNMT-IN-7 can be used in studies of metabolic and chronic diseases .
    NNMT-IN-7
  • HY-163174
    II399

    		Amine N-methyltransferase Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    II399 is a potent, selective NNMT bisubstrate inhibitor containing an unconventional SAM mimic, with a Ki of 5.9 nM. II399 exhibits an explicit pattern of competitive inhibition for NAM. II399 occupies both the substrate and cofactor binding pockets. II399 has the potential for the research of cancers, metabolic, cardiovascular, and neurodegenerative diseases .
    II399
  • HY-151500A
    JBSNF-000028 TFA

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 TFA is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 TFA can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 TFA exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 TFA can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028 TFA
  • HY-111367
    MS2734

    		Amine N-methyltransferase Neurological Disease Metabolic Disease Cancer
    MS2734 is a inhibitor of nicotinamide N-methyltransferase (NNMT). MS2734 potently inhibits the methyltransferase activity of human NNMT (hNNMT) with an IC50 value of 14 μM. MS2734 can be used for the study of obesity, diabetes, Parkinson's disease, and various cancers with high NNMT expression .
    MS2734
  • HY-151500C
    JBSNF-000028

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028
  • HY-RS16748
    Nnmt Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nnmt Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nnmt gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nnmt Mouse Pre-designed siRNA Set A
    Nnmt Mouse Pre-designed siRNA Set A
  • HY-RS09395
    NNMT Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    NNMT Human Pre-designed siRNA Set A contains three designed siRNAs for NNMT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NNMT Human Pre-designed siRNA Set A
    NNMT Human Pre-designed siRNA Set A
  • HY-182021
    NNMT-IN-8

    		Amine N-methyltransferase Endocrinology
    NNMT-IN-8 is a non-SAM-mimicking bisubstrate inhibitor and a selective methyltransferase NNMT inhibitor, with IC50 values of 0.0084 μM and 0.0085 μM against human NNMT, and an IC50 of 0.0072 μM against mouse NNMT. NNMT-IN-8 exhibits prominent renal distribution characteristics and moderate bioavailability in rodents. NNMT-IN-8 dose-dependently inhibits renal NNMT in renal fibrosis models, thereby exerting antifibrotic effects. NNMT-IN-8 can be used to investigate the mechanisms of renal fibrosis .
    NNMT-IN-8
  • HY-RS23186
    Nnmt Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nnmt Rat Pre-designed siRNA Set A contains three designed siRNAs for Nnmt gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nnmt Rat Pre-designed siRNA Set A
    Nnmt Rat Pre-designed siRNA Set A
  • HY-186163
    CC-410

    		Amine N-methyltransferase Metabolic Disease
    CC-410 is a selective Nicotinamide N-methyltransferase (NNMT) inhibitor with a human IC50 value of 1.6 µM. CC-410 impairs terminal adipocyte differentiation via glucocorticoid signaling network deregulation, inhibits adipogenesis and lipid accumulation with time-sensitive activity limited to early adipogenesis stages. CC-410 can be used for the researches of early-onset obesity, glucocorticoid-induced obesity .
    CC-410

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: